Capital Investment Advisory Services LLC Sells 66 Shares of Eli Lilly and Company (NYSE:LLY)

Capital Investment Advisory Services LLC decreased its stake in Eli Lilly and Company (NYSE:LLY) by 1.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,647 shares of the company’s stock after selling 66 shares during the quarter. Capital Investment Advisory Services LLC’s holdings in Eli Lilly and Company were worth $2,709,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Commerzbank Aktiengesellschaft FI raised its position in shares of Eli Lilly and Company by 127.2% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 2,906 shares of the company’s stock valued at $1,694,000 after acquiring an additional 1,627 shares during the period. PSI Advisors LLC raised its holdings in Eli Lilly and Company by 9.8% in the fourth quarter. PSI Advisors LLC now owns 2,962 shares of the company’s stock worth $1,727,000 after purchasing an additional 265 shares during the period. Cetera Trust Company N.A acquired a new stake in Eli Lilly and Company in the fourth quarter worth $1,224,000. LRT Capital Management LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter worth $533,000. Finally, Riggs Asset Managment Co. Inc. increased its position in shares of Eli Lilly and Company by 36.7% in the 4th quarter. Riggs Asset Managment Co. Inc. now owns 3,231 shares of the company’s stock valued at $1,883,000 after buying an additional 868 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Barclays boosted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Bank of America boosted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a report on Monday, April 15th. Finally, Morgan Stanley increased their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 2.6 %

NYSE LLY traded down $19.64 during trading hours on Friday, hitting $726.31. 3,505,526 shares of the company traded hands, compared to its average volume of 2,202,924. The business’s 50-day moving average is $763.96 and its 200-day moving average is $660.53. Eli Lilly and Company has a twelve month low of $369.76 and a twelve month high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The stock has a market capitalization of $690.11 billion, a price-to-earnings ratio of 125.23, a P/E/G ratio of 1.58 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s revenue was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.09 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.